The 500-Dalton rule states that for a substance to be able to cross the skin barrier, it must have a molecular weight of fewer than 500 Daltons. Though there are certain exceptions to this rule, it is generally considered a standard rule of thumb for cosmetic manufacturers. Our innovative technology can overcome this 500-Dalton rule. We find out the super hydrophilic carriers help substances weighing up to 4.5 billion daltons penetrate the skin through the intracellular mechanism. With this technology, we can create an ecosystem of beauty and personal care products with therapeutic properties. Not only that, these products are also aimed at reducing daily water use to preserve clean water for the future. Revenue in the Beauty & Personal Care Vietnamese market amounts to US$2.20 bn in 2022 and grow at a 5.9% compound annual growth rate through 2025. Based on the size of our market and our defined market area, our sales projections for the first year are $30,000. We project a growth rate of 10% per year for the first three years. However, we are planning to change our business model into core technology, formula and materials. With this plan, our revenue is expected to increase 10 times this year.

The major use of seaweed has been predominantly for human consumption. Call to increase consumption has long been made for seaweed gets highly regard as sustainable food potential. Besides its use in functional foods, seaweed also finds its way in processed, powdered forms used as hydrocolloids, texturing agents, and/ or stabilizers, for food, pharmacy, and cosmetic industries. The Global demand for particular use of seaweed in the form of empty capsule for instance, is expected to further increase in an annual growth rate averaging 7.3% per annum since 2016 and is projected to continue until 2026.
　Seaweed as the main input to Inobi’s production system has been becoming an important commodity to support the economy of the coastal area. Indonesia, commonly known as a country with the second longest shore line in the World, has huge potential. Combination of climatological aspect and ecology provides a perfect environment for seaweed cultivation. These facts make seaweed become one of Indonesia’s leading marine commodity in the Global market to date. Currently, Indonesia is the second best world’s seaweed producing country after Chile. Indonesia seaweed production in 2010 reached 3.082 million tons, exceeding the target set by the Ministry of Maritime Affairs and Fisheries (KKP) of 2.574 million tons. Further increase in production of 3.504 million tons in 2011, 5.1 million tons in 2012, 7.5 million tons in 2013. Indonesian seaweeds are commonly produced and exported in the form of dried seaweed and/or semi-finished product for example carrageenan, alginate and gelatine.
　Hard Capsules are solid preparations consisting of drugs in hard or soft shells that can dissolve. The shell is generally made from gelatin. Gelatin is a hydrolysis product from collagen that comes from the skin, tissue and bones of animals that are commonly used, namely from the bones of cattle or buffalo and pig bones. Hard capsule product from seaweed is an alternative gelatin capsule, important for Muslims, Jews, Hindus, Vegetarians and Others on dietary reason. The recent trends of increasing demand for plant based capsule husks finds its explanation not only in the aforementioned communities but more importantly in the changing lifestyle due to the improved awareness and the shift in the value of healthy life, whereby people exempt themselves from animal based- and derivate products and instead opt more for seaweed as healthier option.

・ImmunoACT was founded by Dr Rahul Purwar and incorporated in 2018. It is a spinoff of his bio-science Immunoengineering lab from IIT Bombay which is the premier Science and Technology Institute in India, founded in the year 1958.
・ChimericAntigen Receptor (CAR) T cell therapy has shown enormous potential to revolutionize cancer treatment, and is an FDA approved therapy in USA.
・Currently the therapy is available at an exorbitant price close to USD 1 mio and hence not accessible to millions of terminally-ill patients in the low and middle income countries like India.
・ImmunoACT has indigenously invented the Novel Humanized CAR T therapy which is in advanced stages of human clinical trials for certain types of cancers, more specifically Acute Lymphoblastic Leukemia (ALL) and Diffused Large B Cell Lymphoma (DLBCL).
・This CART Technology has huge potential in curing various types of cancers, including solid tumours that are otherwise non-treatable through current medicine.
・ImmunoACT is also working to use this technology to cure other auto-immune diseases like Sickle Cell Anaemia which has very high prevalence in India.
・Lastly, beyond the commercial success, the social impact of our technology will be significant in India and other developing countries in providing affordable healthcare.

Nanotronics turns highly renewable indigenous plants into nanotechnology materials for use in various industrial applications. Our nanomaterial products serve as key ingredients in the production of advanced materials suited for both conventional and additive manufacturing. Currently, the primary market we are serving is the packaging industry due to the need for sustainable materials.

Paper waste sludge (PWS) is merely a waste of paper industry. PWS contains a large content of pulp cellulose but almost cannot find any valuable application. Without appropriate treatment, PWS cannot be disposed to the environment because it can be bio-dicomposed and fermented that makes ordor smell and organic polution. In our solution, PWS is hydrolyzed with a small amount of acid, then fermented to form thick layers of bacterial cellulose (BC). BC can be collected easily from the fermentation mixture. This is a valuable materials that can be applied for many applications, such as in bio-material synthesis, medical, water treatment processes, packaging, fashion, etc. Some well-known superior properties of BC are biodegradable, good mechanically durable, high biocompatible, non-toxic, etc. To illustrate a potential usage of BC from PWS, we partially hydrolyzed it to obtain nano crystal cellulose (CNC), which is currently known as the most advanced bio-material in the world. CNC is stronger than steel, lighter than wood, transparent film formable, biodegrable, non-toxic, etc. Basic analysis confirmed the feasibility. Although Biomass is in early stage, we already have customers like Anbinh paper industry and Mitsui Chemicals Qroup.

GeneFrontier Corporation (GFC) is a Japanese biotech company, which is one of the group companies of KANEKA Corporation. GFC is focusing on biopharmaceutical R&D support business with innovative products and services especially in the area of protein based biologics including antibodies.

Now, GFC is developing its proprietary technology for R&D of antibody therapeutics, which is a red hot in pharmaceutical industry. As our proprietary product and service, we launched PUREfrex and PUREfrexRD recently. Those are innovative technologies which can contribute to the R&D in pharmaceutical companies developing protein based biologics, such as therapeutic antibodies. It is a simple, fast, easy and effective screening system which can handle highly diversified library. It can remarkably accelerate R&D in pharmaceutical companies.

Our aim is to explore the potential of protein based biologics, and to contribute to the development of innovative therapeutics in healthcare industry through the partnership with pharmaceutical companies.

AyoxxA is a start-up company commercializing a novel technology platform developed at the National University of Singapore. This platform enables the measurement of a large number of different proteins and biomolecular analytes from a very small volume sample – so called “multiplexing” . In the field of genomic analysis, DNA microarrays have become a powerful tool. Yet, despite a rapidly growing multi-billion US$ market for protein analysis, comparable tools are not available at the protein level. AyoxxA addresses this need for multiplexed protein analysis with its platform technology of bead-based protein microarrays on a substrate biochip. This technology will benefit many disciplines, including biological research, pharmacological screening and medical diagnostics.

AyoxxA raised a Series A investment round of 4 Million US$ with several international venture capital companies as well as 1 Million US$ in grants in 2012. For 2013 AyoxxA is looking forward to closing a significantly larger multi-million US$ Series B investment.

The foundation for Apollo Medical Optics Inc. (AMO)’s technology is found at National Taiwan University, where inventors first began investigating the basics of medical optics. These researches eventually led to the development of the advanced technique used for the establishment of AMO’s specialized Optical Coherence Tomography (OCT) system. The difference in the AMO system is due to several factors: the system’s design, the implementation of the single-clad crystal fiber, the development and use of the system’s broadband light source, and the technique’s superior imaging quality. Due to the unique crystal fiber in place in AMO’s OTC system, it provides the AMO system’s images with stronger axial resolution and faster scanning speed when compared to other products. This fundamental technology has already successfully performed non-invasive scans on living patients, giving 3D images of the epidermis, part of the dermis, and the blood flow in capillaries within these areas. With a multidisciplinary and passionate team, AMO believes that the company can become the leading company of non-invasive technology in the world. Our first market will be focused on Mohs surgery (one of the skin cancer treatment), and it could apply our platform to the field of dermatology and pathology.

http://www.apollomedicaloptics.com/